ArticleBMC microbiology2026
Integrated culturomics and 16S rDNA sequencing reveal a functional microbiome signature in endometrial cancer.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveEndometrial cancer (EC) is a common gynecologic malignancy globally, but the role of the intratumoral microbiome remains poorly defined. While microbial dysbiosis is increasingly linked to cancer, the composition, function, and clinical relevance of the microbiota in EC are underexplored. This study aims to systematically profile the microbiome in EC patients by integrating culturomics and 16S rDNA sequencing, and to evaluate the functional properties of key bacterial strains in relation to tumor progression.
methodsWe collected cancerous tissues (CATs), non-cancerous adjacent tissues (NATs), and vaginal swabs from 32 EC patients. Culturomics was performed on 57 samples from 19 patients to isolate and identify bacteria, while 16S rDNA sequencing assessed microbial diversity and composition. Functional assays, including flow cytometry for invasion efficiency and ELISA, were used to evaluate pro-inflammatory capacity.
resultsCulturomics identified 79 bacterial species, with Staphylococcus, Streptococcus, and Cutibacterium emerging as core genera shared across the vagina, NATs, and CATs. Functional analysis revealed that strains such as Staphylococcus epidermidis and Streptococcus anginosus exhibited high invasion efficiency (up to 84.8%) and significantly upregulated pro-inflammatory responses. 16S rDNA sequencing showed that Lactobacillus dominated the vaginal microbiota, whereas endometrial tissues were enriched with opportunistic pathogens (e.g., Stenotrophomonas). Critically, specific genera were associated with aggressive clinical features: Slackia with poorly differentiated (G3) tumors and Porphyromonas with deep myometrial invasion (≥ 50%).
conclusionThis study uncovers a distinct, translocally disseminated core microbiota in EC, with key strains demonstrating invasive and pro-inflammatory capacities that may play a role in tumor progression. These findings provide a foundation for microbial biomarkers and targeted interventions, highlighting the transformative potential of microbiome research in gynecologic oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.